178 related articles for article (PubMed ID: 22301813)
1. Assaying the kinase activity of LRRK2 in vitro.
Lewis PA
J Vis Exp; 2012 Jan; (59):. PubMed ID: 22301813
[TBL] [Abstract][Full Text] [Related]
2. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
Jaleel M; Nichols RJ; Deak M; Campbell DG; Gillardon F; Knebel A; Alessi DR
Biochem J; 2007 Jul; 405(2):307-17. PubMed ID: 17447891
[TBL] [Abstract][Full Text] [Related]
3. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities.
Liu M; Dobson B; Glicksman MA; Yue Z; Stein RL
Biochemistry; 2010 Mar; 49(9):2008-17. PubMed ID: 20146535
[TBL] [Abstract][Full Text] [Related]
4. Development of a high-throughput AlphaScreen assay measuring full-length LRRK2(G2019S) kinase activity using moesin protein substrate.
Pedro L; PadrĂ³s J; Beaudet L; Schubert HD; Gillardon F; Dahan S
Anal Biochem; 2010 Sep; 404(1):45-51. PubMed ID: 20434426
[TBL] [Abstract][Full Text] [Related]
5. Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment.
Klein CL; Rovelli G; Springer W; Schall C; Gasser T; Kahle PJ
J Neurochem; 2009 Nov; 111(3):703-15. PubMed ID: 19712061
[TBL] [Abstract][Full Text] [Related]
6. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity.
Guo L; Gandhi PN; Wang W; Petersen RB; Wilson-Delfosse AL; Chen SG
Exp Cell Res; 2007 Oct; 313(16):3658-70. PubMed ID: 17706965
[TBL] [Abstract][Full Text] [Related]
7. Contribution of GTPase activity to LRRK2-associated Parkinson disease.
Tsika E; Moore DJ
Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585
[TBL] [Abstract][Full Text] [Related]
8. The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties.
Mills RD; Liang LY; Lio DS; Mok YF; Mulhern TD; Cao G; Griffin M; Kenche VB; Culvenor JG; Cheng HC
J Neurochem; 2018 Nov; 147(3):409-428. PubMed ID: 30091236
[TBL] [Abstract][Full Text] [Related]
9. Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities.
Webber PJ; Smith AD; Sen S; Renfrow MB; Mobley JA; West AB
J Mol Biol; 2011 Sep; 412(1):94-110. PubMed ID: 21806997
[TBL] [Abstract][Full Text] [Related]
10. Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers.
Civiero L; Vancraenenbroeck R; Belluzzi E; Beilina A; Lobbestael E; Reyniers L; Gao F; Micetic I; De Maeyer M; Bubacco L; Baekelandt V; Cookson MR; Greggio E; Taymans JM
PLoS One; 2012; 7(8):e43472. PubMed ID: 22952686
[TBL] [Abstract][Full Text] [Related]
11. Identification of the autophosphorylation sites of LRRK2.
Kamikawaji S; Ito G; Iwatsubo T
Biochemistry; 2009 Nov; 48(46):10963-75. PubMed ID: 19824698
[TBL] [Abstract][Full Text] [Related]
12. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding.
Taymans JM; Vancraenenbroeck R; Ollikainen P; Beilina A; Lobbestael E; De Maeyer M; Baekelandt V; Cookson MR
PLoS One; 2011; 6(8):e23207. PubMed ID: 21858031
[TBL] [Abstract][Full Text] [Related]
14. Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions.
Drolet RE; Sanders JM; Kern JT
J Neurogenet; 2011 Dec; 25(4):140-51. PubMed ID: 22077787
[TBL] [Abstract][Full Text] [Related]
15. Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2.
Covy JP; Giasson BI
Biochem Biophys Res Commun; 2009 Jan; 378(3):473-7. PubMed ID: 19027715
[TBL] [Abstract][Full Text] [Related]
16. Conformational heterogeneity of the Roc domains in C. tepidum Roc-COR and implications for human LRRK2 Parkinson mutations.
Rudi K; Ho FY; Gilsbach BK; Pots H; Wittinghofer A; Kortholt A; Klare JP
Biosci Rep; 2015 Aug; 35(5):. PubMed ID: 26310572
[TBL] [Abstract][Full Text] [Related]
17. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites.
Greggio E; Taymans JM; Zhen EY; Ryder J; Vancraenenbroeck R; Beilina A; Sun P; Deng J; Jaffe H; Baekelandt V; Merchant K; Cookson MR
Biochem Biophys Res Commun; 2009 Nov; 389(3):449-54. PubMed ID: 19733152
[TBL] [Abstract][Full Text] [Related]
18. Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays.
Anand VS; Reichling LJ; Lipinski K; Stochaj W; Duan W; Kelleher K; Pungaliya P; Brown EL; Reinhart PH; Somberg R; Hirst WD; Riddle SM; Braithwaite SP
FEBS J; 2009 Jan; 276(2):466-78. PubMed ID: 19076219
[TBL] [Abstract][Full Text] [Related]
19. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.
Nichols RJ; Dzamko N; Hutti JE; Cantley LC; Deak M; Moran J; Bamborough P; Reith AD; Alessi DR
Biochem J; 2009 Oct; 424(1):47-60. PubMed ID: 19740074
[TBL] [Abstract][Full Text] [Related]
20. Human leucine-rich repeat kinase 1 and 2: intersecting or unrelated functions?
Civiero L; Bubacco L
Biochem Soc Trans; 2012 Oct; 40(5):1095-101. PubMed ID: 22988872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]